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Abstract 
Background: To determine the effects of previous 
overt hyperthyroidism due to Graves’ disease on 
BMD in euthyroid pre and post menopausal females. 
Methods: In this cross-sectional, non-
interventional study,fifty patients with previous 
hyperthyroidism due to Graves’ disease 
(premenopausal:25, postmenopausal: 25) who 
remained euthyroid for at least 6 months prior to 
study were included and compared with fifty- 
matched respective controls. Free thyroxine (FT4), 
TSH, and BMD were measured. Comparison was 
made between two groups and also between patients 
and controls in each group.  
Results: Statistically significant (p <.0.05) lower 
whole body BMD expressed as Z-score was observed 
in post-menopausal women having history of 
hyperthyroidism due to Graves’ disease than 
matched controls.  Bone mineral density, expressed 
as Z-score in whole body and lumbar spine was 
significantly lower in group II (post-menopause) in 
comparison to group I (pre-menopause) patients. 
Time of euthyroidism and time of evolution of 
disease has significant effect on BMD in post-
menopausal women.  
Conclusion: Graves’ hyperthyroidism affects BMD 
only in post menopausal females even after 
achievement of euthyroid status.  
Key Words: Hyperthyroidism , Graves’ disease, 
Bone mineral density (BMD) , Post menopausal 
females 
 
Introduction 
Patients with hyperthyroidism may develop secondary 
osteoporosis. In such patients, high concentrations of 
triiodothyronine play a role. However, the 
normalization of the thyroid hormone levels 
(euthyroidism) has also positive effects on bone 
metabolism in such patients. Moreover, it is unclear, 
whether, menopause status aggravates this condition 
of osteoporosis or not.Reduction in bone mineral 
density (BMD) following hyperthyroidism in female 
subjects has been described in many reports.1-7 
Hyperthyroidism can be considered as one of the 
major causes of secondary osteoporosis. It has also 
been suggested that the past history of Graves’ disease 
itself, and not the current state of thyroid function, was 
responsible for bone loss in women receiving long-
term levothyroxine therapy.8  It has been shown that in 
patients with hyperthyroidism the increase in bone 
resorption was more prominent in cortical as 
compared to cancellous bone.9, 10 Thyroid hormones 
exert their effect on osteoblasts via nuclear receptors 
stimulating osteoclastic bone resorption. 11-13 
Significant attenuation of bone is followed by increase 
in lumbar spine BMD with normalization of thyroid 
function.14 
Different studies have shown association of different 
thyroid related factors which can cause reduction in 
bone mineral density. Significant correlation has been 
shown between two types of antibodies i.e TSH 
receptor antibodies and thyroid stimulating antibodies 
with a reduction in BMD in distal radius of male 
patients with untreated Graves’ disease.  Moreover, 
higher levels of thyroid stimulating antibodies have 
shown significant correlation with urinary N-terminal 
telopeptide.15  It has been shown in mice that TSH 
affects bone metabolism through TSH receptors found 
on osteoblast and osetoclast precursors .16  
Patients and Methods 
Total 50 patients were included in the study and 
compared with control subjects (age and gender 
matched).Patients with previous history of Graves’ 
disease and persistent euthyroidism for at least 
6 months (before entering the study) were included in 
the study.  The diagnosis of Graves’ disease had been 
established by the presence of symptoms and signs of 
hyperthyroidism, diffuse goitre, ophthalmopathy 
and/or positive TRAb, high serum concentrations of 
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free thyroxine (FT4) and triiodothyronine (T3) and 
suppressed TSH. Ultimate treatment was achieved 
with antithyroid drugs in six patients and radioiodine 
in forty six patients. All patients had at least two FT4 
and TSH values within the normal range for at least 
6 months prior to this study.Patients with history of 
fracture prior to the beginning of the disease, non-
thyroidal illness (liver disease, renal dysfunction, 
malignancy, diabetes mellitus, hyperparathyroidism, 
hypercortisolism, or hypogonadism) or intake of drugs 
(active vitamin D3, bisphosphonates, calcitonin, 
testosterones, steroids, diuretics, heparin, or 
anticonvulsants) that could influence bone metabolism 
and early menopause were excluded. All subjects 
underwent plain x-ray (anteroposterior and lateral 
views) of the lumbar spine, and those found to have 
scoliosis, compression fractures, or ectopic 
calcifications that could interfere with the bone 
mineral density (DEXA scan) results were also 
excluded. 
Patients were divided into two groups according to 
their menopausal status at the moment of the study. 
Group I included premenopausal (n = 25) and Group 
II included postmenopausal (n = 25). Menopause was 
defined as one year of amenorrhea and high levels of 
FSH.Both groups were compared with 50 euthyroid 
controls matched according to age, gender, and 
anthropometrical status (Premenopausal controls n = 
30 and Postmenopausal controls n = 20).  
Time of hyperthyroidism was taken as  the sum of all 
the periods in which the patient had high levels of 
thyroid hormones and suppressed TSH levels 
(including relapses). Time of euthyroidism was taken 
as the time when patient has first permanently normal 
FT4 and TSH levels post-treatment till inclusion in the 
study.Total time of evolution of disease  included sum 
of both periods: hyperthyroidism and 
euthyroidism.Thyroid function variables: FT4 and TSH 
were measured using commercially available kits 
(ELISA).Total calcium, phosphorus and creatinine 
were measured in serum using standard laboratory 
methods.Serum intact parathyroid hormone levels 
were measured by an Immulite 1000 with intra-and 
interassay CVs of 5.5% and 7.9%, respectively. Serum 
total 25-hydroxyvitamin D (25OHD) was measured by 
ELISA. 
Bone Mineral Density measurements were done by 
employing (DEXA Scan)(Figure 1).These were   
performed at the Lumbar spine (L2-L4), hip and whole 
body by dual energy X-ray absorptiometry (Explorer, 
Hologic ) (Figure  2). Values of BMD were expressed 
as the mean in g/cm2 and Z-scores on the basis of 
normal reference values of an age and gender-matched 
group provided by the DEXA system manufacturer. 
The same operator measured all the subjects. The 
phantom precision expressed as the CV (%) was 0.83. 
p-values were calculated. A p-value of less than 0.05 
(<0.05) was considered as significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Dexa scan with equipment used for BMD 
estimation of the study population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: DEXA scan images. a; lumbar spine, b; 
femoral neck, c; whole body 
Results 
The patients in both groups (pre-menopausal and post 
menopausal) did not show significant difference in 
demographic data, osteoporotic risk factors or in  
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Table 1: Data of patients and controls  
in both groups 
 
Group-I 
D(n = 25) 
Group-IC 
(n = 30) P 
Group-II D 
(n = 25) 
Group-IIC 
(n = 20) P 
Age 
(years) 37.4± 8.8 36.9± 10.1 ns 57.1± 6.1 56.4± 6.8 Ns 
Age of 
menarche 
(years) 13.1± 1.2 12.9 + 1.1 ns 12.8 ± 0.5 12.9 ± 0.9 Ns 
Age of 
menopaus
e (years) - - ns 48.1± 4.8 47.9± 4.6 Ns 
BMI 24.8± 3.9 23.6± 4.0 ns 26.4± 4.8 27.9±4.5 Ns 
Calcium 
intake 
(gr/day) 
260 (30–
1125) 
430 (120–
1209) ns 
815 (202–
1590) 
290 (62–
899) 
<0.00
3 
Serum 
calcium 
(mg/dL) 9.4± 0.5 9.4± 0.4 ns 9.4± 0.4 9.4± 0.4 Ns 
Serum 
phosphor
ous 
(mg/dL) 3.6± 0.5 3.5± 0.6 ns 4.0± 0.5 3.9± 0.6 Ns 
Serum 
creatinine 
(mg/dL) 0.8± 0.1 0.7± 0.1 ns 0.7 + 0.1 0.8 + 0.1 Ns 
PTH 
(ug/mL) 60.1± 29.8 52.9± 17.6 ns 58.3± 19.1 55.7± 20.3 Ns 
25OHD 
(ng/mL) 30.1± 10.2 38.6± 19.8 ns 29.8± 18.1 36.7± 13.1 Ns 
BMD L2-
L4 
(gr/cm2) 1.05± 0.13 1.02± 0.16 ns 1.06± 0.14 1.05± 0.12 Ns 
BMD L2-
L4 (z-
score) 0.09± 1.12 0.06± 1.0 ns −0.41± 1.15 −0.50± 0.75 Ns 
BMD FN 
(gr/cm2) 0.96± 0.11 0.97± 0.13 ns 0.83± 0.15 0.85± 0.12 Ns 
BMD FN 
(z-score) 0.13± 0.7 0.09±0.6 ns −0.48± 0.74 −0.49± 0.91 Ns 
BMD WB 
(gr/cm2) 1.15± 0.07 1.13± 0.08 ns 0.98± 0.14 1.12± 0.10 
<0.00
3 
BMD WB 
(z-score) 0.22± 0.73 0-70± 0,42 ns −0.79 + 1.1 0.52 ± 1.1 
<0.00
6 
Data are presented as means ± SD. Lumbar spine (L2-L4), 
FN; femoral neck, WB; whole body. Group ID 
(Premenopausal patients) Group I C (Pre-menopausal 
controls) Group II D (Post-menopausal patients), Group II C 
(Post menopausal controls)  
 
Table 2: Characteristics of Graves’ disease in 
patients of both groups 
 
Group-I (n 
= 25) 
Group-II (n = 
25) P 
Age of beginning of the 
disease (years) 31.2± 6.9 42.1± 9.9 0.006 
Time of hyperthyroidism 
(months) 36.1±38.7 50.6±80.1 Ns 
Time of euthyroidism 
(months) 66.2± 54 138.6± 120.8 0.005 
Time of evolution of 
disease (months) 96.2±76.3 180.9± 121.2 0.001 
Euthyroid patients with T4 
(%) 58 94 0.002 
T4 (ug/dL) 10.1± 1.8 9.8± 1.6 Ns 
TSH (uUI/mL) 1-8± 1.1 1.7± 1.2 Ns 
Data are presented as means ± SD. Group-I Premenopausal 
Graves Disease, Group-II Postmenopausal Graves Disease. 
biochemical parameters in comparison to their control 
groups (Table 1). Comparsion of both groups (Group I 
and Group II) showed no significant differences risk 
factors for osteoporosis and/or biochemical data of 
mineral metabolism. The pre-menopausal group 
(Group-I) presented BMD similar to their respective 
controls in all the regions studied and postmenopausal 
women (Group-II) only presented significant 
difference in whole body BMD than controls (lower 
whole body BMD) (Table 1). Post menopausal females 
(Group-II) showed significantly lower BMD Z-scores 
in whole body and lumbar spine as compared to 
premenopausal group (Figure 1).Calcium intake was 
significantly higher in the postmenopausal than in the 
premenopausal group (p < 0.003). It was also observed 
that patients in postmenopausal group had beginning 
of their disease at an older age showing a longer time 
of euthyroidism and a longer time of evolution of the 
disease. The patients having thyroxin replacement 
therapy was more in postmenopausal group as 
compared to pre-menopausal group. No significant 
differences were found in the levels of T4, TSH in both 
groups (Table 2).  
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Figure 3: Bone mineral density expressed as Z-score in WB, 
FN and L2-L4 in premenopausal (n = 25) vs 
postmenopausal patients (n = 25) with a history of 
hyperthyroidism due to Graves’ disease. *: p < 0.005, **: p < 
0.0002. W-B: whole body; FN: femoral neck; L2-L4: lumbar 
spine; Pre-MP: premenopausal; Post-MP: postmenopausal. 
 
Discussion 
Active thyrotoxicosis resulted in a 12–15% reduction of 
BMD, predominantly in cortical bone .17 Several small 
studies have been devised to assess the change in bone 
mass after treatment of hyperthyroidism. Although all 
of these studies have demonstrated improvement in 
bone density after restoration of the euthyroid state, 
the amount of improvement and the time frame 
evaluated varied considerably, the populations 
studied on the different surveys were heterogeneous 
with reference to etiology of hyperthyroidism, 
osteoporosis risk factors and menopausal status.18-22 
The long-term effects of treated thyrotoxicosis remain 
uncertain, but most studies suggest a persistent two to 
threefold increased relative risk for hip fracture, 
mainly in postmenopausal women. 23-27 
Hyperthyroidism has been shown to accelerate bone 
turnover  and shorten the normal bone remodeling 
cycle.23,28 
Both estradiol and T3 are essential for normal bone 
turnover in vivo. This has been shown by the skeletal 
phenotypes of aromatase-deficient mice, human 
aromatase deficiency and postmenopausal women.29  
Estrogen status influences thyroid hormones and TSH 
effects on bone mass. It has been shown  that acute 
TSH administration in postmenopausal women 
resulted in an increase of serum N-terminal pro-
peptide of type-I pro-collagen, an index of osteoblastic 
activity. 30  Lack of this response in premenopausal 
women suggested an influence of estrogen status on 
bone reactivity to TSH. 
In our cross-sectional study, postmenopausal patients 
with past history of Graves’ disease hyperthyroidism, 
presently having normal TSH and FT4 levels and 
longstanding euthyroidism, were investigated and 
analyzed in two groups (pre-menopausal and post-
menopausal). The results showed that premenopausal 
population (Group I) showed no differences in BMD in 
relation to their matched controls; while 
postmenopausal population showed a lower whole 
body BMD in relation to their matched controls. 
Patients with hyperthyroidism may experience cortical 
bone loss as it has been shown that thyroid hormone 
excess causes mainly cortical bone loss , even in non-
autoimmune hyperthyroid multinodular goiters.31,32  
There was significant difference in The BMD values of 
both groups. The post-menopausal group showed 
lower lumbar spine as well as whole body BMD z-
score values. This difference cannot be only due to 
postmenopausal status as it was avoided using Z score 
(on the basis of normal reference values of age- and 
gender-matched group) instead of T-score (on the 
basis of normal reference values of young age and 
gender-matched group provided by the DEXA system 
manufacturer). The other parameters including 
duration of hyperthyroidism, FT4 and TSH values 
were almost similar in both groups. The time of 
persistent euthyroidism was 6 months or more (as a 
part of inclusion criteria) before entering the study 
may have introduced a bias due to the short time 
interval for re-establishing normal BMD-levels, but the 
medium time of persistent euthyroidism was longer in 
postmenopausal women (66.2 months in pre-
menopausal group and 138.6 months postmenopausal 
group).  
Moreover, the age at the onset of hyperthyroidism has 
also shown significant difference in the patients. This 
shows that beginning of hyperthyroidism at 
perimenopause age, which is time of great 
vulnerability of bone mass  has more pronounced 
negative effects on bone density. 33 This finding is 
further strengthened in the study by the observation 
that patients in postmenopausal group with a previous 
history of perimenopausal hyperthyroidism, despite a 
long time of euthyroidism, had a lower bone mass 
than matched controls. Whereas, patients in pre-
menopuase group did not show any difference from 
matched controls. 
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